What medications are recommended for women with lower urinary tract symptoms (LUTS) such as urgency, frequency, mixed or stress urinary incontinence, including considerations for postmenopausal patients?

Medications for Women with LUTS

For women with urgency urinary incontinence (UUI) who fail bladder training, use antimuscarinics with selection based on tolerability—specifically choose darifenacin, tolterodine, or solifenacin as they have the lowest discontinuation rates due to adverse effects, while avoiding oxybutynin which has the highest discontinuation rate. 1

Treatment Algorithm by LUTS Type

Stress Urinary Incontinence

• Do NOT use systemic pharmacologic therapy for stress incontinence 1
• Vaginal estrogen formulations improve stress UI in postmenopausal women 1, 2
• Systemic estrogen (transdermal patches) actually worsens UI and should be avoided 1

Urgency Urinary Incontinence (UUI)

First-line: Bladder training (non-pharmacologic) 1

Second-line pharmacotherapy (if bladder training unsuccessful):

Preferred antimuscarinics (lowest adverse effect discontinuation rates):

• Darifenacin - discontinuation rate similar to placebo 1
• Tolterodine - discontinuation rate similar to placebo 1
• Solifenacin - lowest overall discontinuation risk among all agents 1

Alternative antimuscarinics (higher discontinuation rates):

• Fesoterodine - moderate discontinuation risk 1
• Trospium - higher discontinuation risk 1
• Oxybutynin - AVOID as first choice - highest discontinuation rate (NNTH=16) 1

Beta-3 agonist:

• Mirabegron - causes nasopharyngitis and GI disorders rather than anticholinergic effects 1

Combination therapy for refractory UUI:

• Solifenacin 5mg + mirabegron 50mg shows superior efficacy to either monotherapy with additive effect sizes 3
• Adverse events (dry mouth, constipation, urinary retention) increase with combination therapy 3

Mixed Urinary Incontinence

• Pelvic floor muscle training (PFMT) combined with bladder training is first-line 1
• If non-pharmacologic fails, follow UUI medication algorithm above

Postmenopausal Women with Dysuria, Frequency, or Recurrent UTI

• Vaginal estrogen is the treatment of choice 2, 4
• Improves dysuria, frequency, urge incontinence, stress incontinence, and reduces recurrent UTI 2
• Intravaginal DHEA and ospemifene are alternatives 4

Key Adverse Effects to Counsel Patients About

Antimuscarinics: Dry mouth, constipation, blurred vision 1

• Oxybutynin has highest risk of hallucinations 1

Mirabegron: Nasopharyngitis, GI disorders 1

Critical consideration: All antimuscarinics are equally efficacious for UUI, so selection must be based on tolerability and adverse effect profile rather than efficacy 1

Common Pitfalls to Avoid

1. Never use systemic pharmacotherapy for pure stress incontinence - it doesn't work 1
2. Don't prescribe transdermal estrogen for UI - it worsens symptoms 1
3. Avoid starting with oxybutynin - while effective, it has 7-fold higher discontinuation rate than tolterodine (NNTH=14) 1
4. Don't skip behavioral interventions - they're cheaper, equally effective for many patients, and have minimal adverse effects 1
5. Screen for urinary retention risk before combination therapy, especially in elderly women 3

Special Population: Women ≥65 Years

These vulnerable patients have higher LUTS severity and worse quality of life 5. Start with lower doses, monitor closely for anticholinergic effects (confusion, falls), and consider mirabegron as alternative to avoid cognitive side effects.